Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
// Lorenzo Nicolè 1, * , Tiziana Sanavia 2, * , Nicola Veronese 3 , Rocco Cappellesso 1, 7 , Claudio Luchini 4, 5, 6 , Paolo Dabrilli 1 , Ambrogio Fassina 1 1 Department of Medicine, Surgical Pathology & Cytopathology Unit, University of Padova, Padova, Italy 2 Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA 3 National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy 4 Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy 5 ARC-NET Research Center, University and Hospital Trust of Verona, Verona, Italy 6 Department of Pathology, Santa Chiara Hospital, Trento, Italy 7 Pathological Anatomy and Histology Unit, Veneto Institute of Oncology, Padova, Italy * These authors have contributed equally to this work Correspondence to: Ambrogio Fassina, email: ambrogio.fassina@unipd.it Keywords: SALL4, cancer, prognosis, meta-analysis, targeted therapy Received: April 05, 2016 Accepted: January 06, 2017 Published: February 01, 2017 ABSTRACT The Spalt-Like Transcription Factor 4 (SALL4) oncogene plays a central function in embryo-fetal development and is absent in differentiated tissues. Evidence suggests that it can be reactivated in several cancers worsening the prognosis. We aimed at investigating the risk associated with SALL4 reactivation for all-cause mortality and recurrence in cancer using the current literature. A PubMed and SCOPUS search until 1st September 2016 was performed, focusing on perspective studies reporting prognostic parameters in cancer data. In addition, 17 datasets of different cancer types from The Cancer Genome Atlas were considered. A total of 9,947 participants across 40 cohorts, followed-up for about 5 years on average, were analyzed comparing patients showing SALL4 presence (SALL4+, n = 1,811) or absence (SALL4-, n = 8,136). All data were summarised using risk ratios (RRs) for the number of deaths/recurrences and hazard ratios (HRs) for the time-dependent risk related to SALL4+, adjusted for potential confounders. SALL4+ significantly increased overall mortality (RR = 1.34, 95% confidence intervals (CI)=1.21-1.48, p<0.0001, I 2 =66%; HR=1.4; 95%CI: 1.19-1.65; p<0.0001; I 2 =63%) and recurrence of disease (RR = 1.25, 95% CI = 1.1-1.42, p=0.0006, I 2 =62%); HR=1.52; 95% CI: 1.22-1.89, p=0.0002; I 2 =69%) compared to SALL4-. Moreover, SALL4 remained significantly associated with poor prognosis even using HRs adjusted for potential confounders (overall mortality: HR=1.4; 95%CI: 1.19-1.65; p<0.0001; I 2 =63%; recurrence of disease: HR=1.52; 95% CI: 1.22-1.89, p=0.0002; I 2 =69%). These results suggest that SALL4 expression increases both mortality and recurrence of cancer, confirming this gene as an important prognostic marker and a potential target for personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J., Tam, W.-L., Tong, G. Q., Wu, Q., Chan, H.-Y., Soh, B.-S., Lou, Y., Yang, J., Ma, Y., Chai, L., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1481 · Cited by 568
Al-Baradie, R., Yamada, K., St. Hilaire, C., Chan, W.-M., Andrews, C., McIntosh, N., Nakano, M., Martonyi, E. J., Raymond, W. R., Okumura, S., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/343821 · Cited by 314 · cited 1×
“Homozygous loss-of function mutation of SALL4 are lethal for the embryo, while heterozygous mutations cause renal-ocular syndrome and the Okihiro syndrome, associated with multi limbs defects, deficient eye movements, renal malformations, and deafness [32].”
BackgroundOncofetal Gene SALL4 in Aggressive Hepatocellular Carcinoma
Yong, K. J., Gao, C., Lim, J. S. J., Yan, B., Yang, H., Dimitrov, T., Kawasaki, A., Ong, C. W., Wong, K.-F., Lee, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300297 · Cited by 257
Lim, C. Y., Tam, W.-L., Zhang, J., Ang, H. S., Jia, H., Lipovich, L., Ng, H.-H., Wei, C.-L., Sung, W. K., Robson, P., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.08.004 · Cited by 224
Lu, J., Jeong, H., Kong, N., Yang, Y., Carroll, J., Luo, H. R., Silberstein, L. E., YupoMa, & Chai, L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005577 · Cited by 168 · cited 1×
“In addition, SALL4 complex can control gene accessibility recruiting the epigenetic repressor complex Mi-2/ Nucleosome Remodelling and Deacetylase (NuRD) involved in Phosphatase and TENsin homologue (PTEN) and other SALL-family genes down-regulation [35].”
BackgroundA Novel SALL4/OCT4 Transcriptional Feedback Network for Pluripotency of Embryonic Stem Cells
Yang, J., Gao, C., Chai, L., & Ma, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010766 · Cited by 152 · cited 1×
“As for OCT4, evidence suggests that SALL4 is a major stemness factor and both SALL4 and OCT4 are expressed from the 2-cells stage embryo [33].”
BackgroundKohlhase, J., Schuh, R., Dowe, G., Kühnlein, R. P., Jäckle, H., Schroeder, B., Schulz-Schaeffer, W., Kretzschmar, H. A., Köhler, A., Müller, U., et al. (1996) · Genomics · doi:10.1006/geno.1996.0631 · Cited by 145
The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma
Zeng, S. S., Yamashita, T., Kondo, M., Nio, K., Hayashi, T., Hara, Y., Nomura, Y., Yoshida, M., Hayashi, T., Oishi, N., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.024 · Cited by 140
SALL4, the missing link between stem cells, development and cancer
Tatetsu, H., Kong, N. R., Chong, G., Amabile, G., Tenen, D. G., & Chai, L. (2016) · Gene · doi:10.1016/j.gene.2016.02.019 · Cited by 130 · cited 2×
“Putative upstream regulators of SALL4 include several promoter activators such as the Signal Transducer and Activator of Transcription 3 (STAT3), the Wnt/β-catenin pathway, and the Caudal type homeobox 1 (CDX1) [6].”
BackgroundHe, J., Zhou, M., Chen, X., Yue, D., Yang, L., Qin, G., Zhang, Z., Gao, Q., Wang, D., Zhang, C., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0378-z · Cited by 85
Cited by
SALL Proteins; Common and Antagonistic Roles in Cancer
Álvarez, C., Quiroz, A., Benítez-Riquelme, D., Riffo, E., Castro, A. F., & Pincheira, R. (2021) · Cancers · doi:10.3390/cancers13246292 · Cited by 37
SALL4: An Intriguing Therapeutic Target in Cancer Treatment
Moein, S., Tenen, D. G., Amabile, G., & Chai, L. (2022) · Cells · doi:10.3390/cells11162601 · Cited by 35
“These data indicate that SALL4 is associated with a poor survival rate and suggests it as a potential biomarker of cancer prognosis [6].”
BackgroundSALL4 in gastrointestinal tract cancers: upstream and downstream regulatory mechanisms
Wang, T., Jin, Y., Wang, M., Chen, B., Sun, J., Zhang, J., Yang, H., Deng, X., Cao, X., Wang, L., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00812-z · Cited by 9
Metadata
- Authors
- Nicolè, L., Sanavia, T., Veronese, N., Cappellesso, R., Luchini, C., Dabrilli, P., & Fassina, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-02-01
- Volume
- 8
- Issue
- 14
- Pages
- 22968-22979
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2583443690
- Cited by
- 39
- References
- 13
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.